Adaptimmune Therapeutics PLC - Company Profile (NASDAQ:ADAP)

About Adaptimmune Therapeutics PLC -

Adaptimmune Therapeutics PLC - logoAdaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company's TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADAP
  • CUSIP:
Key Metrics:
  • Previous Close: $3.95
  • 50 Day Moving Average: $4.28
  • 200 Day Moving Average: $5.32
  • 52-Week Range: $70,785,000.00 - $3.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.29
  • P/E Growth: 0.28
  • Market Cap: $279.60M
  • Outstanding Shares: 70,785,000
  • Beta: 1.46
Profitability:
  • Net Margins: -667.22%
  • Return on Equity: -31.56%
  • Return on Assets: -25.90%
Debt:
  • Current Ratio: 8.81%
  • Quick Ratio: 8.81%
Additional Links:
Companies Related to Adaptimmune Therapeutics PLC -:

Analyst Ratings

Consensus Ratings for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) (?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $15.50 (292.41% upside)

Analysts' Ratings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetDetails
11/11/2016Leerink SwannReiterated RatingBuy$15.00View Rating Details
11/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details
10/24/2016Bank of America CorpDowngradeNeutral -> UnderperformView Rating Details
9/30/2016Raymond James Financial, Inc.Initiated CoverageOutperform$16.00View Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyView Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$15.00View Rating Details
12/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$16.00View Rating Details
6/1/2015GuggenheimInitiated CoverageBuy$25.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
5/12/2016Q1($0.19)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-1.20 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.20)($0.16)($0.18)
Q2 20163($0.26)($0.19)($0.22)
Q3 20162($0.20)($0.18)($0.19)
Q4 20162($0.26)($0.24)($0.25)
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Institutional Ownership Percentage: 43.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2016Orbimed Advisors LlcDirectorBuy1,712,400$10.42$17,843,208.00View SEC Filing  
5/19/2016Charles Elliott SigalDirectorBuy15,000$1.56$23,400.00View SEC Filing  
5/18/2016Charles Elliott SigalDirectorBuy45,000$1.53$68,850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
DateHeadline
News IconTrading Insight: Taking a Look at Levels for Adaptimmune Therapeutics PLC (ADAP) - Davidson Register (NASDAQ:ADAP)
davidsonregister.com - February 24 at 8:20 PM
News IconInvestor Corner: Checking in on Shares of Adaptimmune Therapeutics PLC (ADAP) - Baxter Review (NASDAQ:ADAP)
baxternewsreview.com - February 24 at 3:20 PM
finance.yahoo.com logoAdaptimmune to Participate in Upcoming Investor Conference (NASDAQ:ADAP)
finance.yahoo.com - February 17 at 6:47 PM
sbwire.com logoNew Report Available: Melanoma - Pipeline Review, H2 2016 (NASDAQ:ADAP)
www.sbwire.com - February 16 at 3:21 PM
nasdaq.com logoEuropean ADRs Edge Higher as Pharma Stocks See Mixed Fortunes (NASDAQ:ADAP)
www.nasdaq.com - February 16 at 3:21 PM
News IconStock Update on Earnings & Estimates for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) - Aiken Advocate (NASDAQ:ADAP)
aikenadvocate.com - February 14 at 3:33 PM
sbwire.com logoNew Report Available: Breast Cancer - Pipeline Review, H2 2016 (NASDAQ:ADAP)
www.sbwire.com - February 10 at 3:22 PM
globenewswire.com logoAdaptimmune to Participate in Upcoming Investor Conference - GlobeNewswire (press release) (NASDAQ:ADAP)
globenewswire.com - February 9 at 3:19 PM
investornewswire.com logoCan Shares Of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Hit $16? - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - February 9 at 1:25 AM
istreetwire.com logoTrader Alert: Merck & Co., Inc. (MRK), Wal-Mart Stores, Inc. (WMT), CSX Corporation (CSX) (NASDAQ:ADAP)
istreetwire.com - February 7 at 3:24 PM
News IconEsophageal Cancer - Pipeline Review, H2 2016 - New Study Released (NASDAQ:ADAP)
reports.pr-inside.com - February 3 at 3:25 PM
News IconT-Cell Immunotherapy, A Novel Advancement For the Treatment Of Cancer (NASDAQ:ADAP)
www.abnewswire.com - February 2 at 3:19 PM
News IconStock Update on Earnings & Estimates for Adaptimmune ... - Aiken Advocate (NASDAQ:ADAP)
aikenadvocate.com - February 2 at 1:25 AM
biz.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ADAP)
biz.yahoo.com - January 31 at 8:26 PM
News IconStock Update on Earnings & Estimates for Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Aiken Advocate (NASDAQ:ADAP)
aikenadvocate.com - January 31 at 3:23 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)? - Wall Street Beacon (NASDAQ:ADAP)
wsbeacon.com - January 31 at 3:23 PM
News IconIt Seems Adaptimmune Therapeutics PLC – ADR (ADAP) Will Go Down. Formed A Few Months Double Bottom (NASDAQ:ADAP)
randolphguide.com - January 30 at 8:31 PM
News IconAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Analyst Coverage - NewsDen (NASDAQ:ADAP)
newsden.net - January 28 at 2:48 AM
investornewswire.com logoStrong Sell Recommendations Of Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) At 0 - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - January 26 at 1:25 AM
News IconEarnings in Full Force, Analysts Take Aim at Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) - Wall Street Beacon (NASDAQ:ADAP)
wsbeacon.com - January 26 at 1:25 AM
News IconIs Trouble Brewing For This Stock? Shares Gapping Lower: Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Aiken Advocate (NASDAQ:ADAP)
aikenadvocate.com - January 25 at 8:25 PM
News IconEarnings in Full Force, Analysts Take Aim at Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) - Wall Street Beacon (NASDAQ:ADAP)
wsbeacon.com - January 25 at 3:23 PM
News IconStock Perspective: Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Earnings in View - Aiken Advocate (NASDAQ:ADAP)
aikenadvocate.com - January 18 at 3:47 PM
investornewswire.com logoAdaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - January 18 at 3:47 PM
News IconObsEva SA - ObsEva Expands Leadership Team and Board of Directors with Industry Veterans (NASDAQ:ADAP)
www.romandie.com - January 18 at 1:47 AM
News IconWill The Needle Move For Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ADAP)
wsbeacon.com - January 17 at 3:41 PM
News IconObsEva Expands Leadership Team and Board of Directors with Industry Veterans (NASDAQ:ADAP)
www.econotimes.com - January 17 at 10:17 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Wall Street Beacon (NASDAQ:ADAP)
wsbeacon.com - January 14 at 3:18 PM
istreetwire.com logo3 Notable Runners: Merck & Co., Inc. (MRK), Immune Pharmaceuticals, Inc. (IMNP), Citigroup Inc. (C) (NASDAQ:ADAP)
istreetwire.com - January 13 at 3:35 PM
News IconWho is Everton target Ishak Belfodil? (NASDAQ:ADAP)
www.newsoneplace.com - January 12 at 1:28 AM
investornewswire.com logoAdaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) Strong Sell Recommendations At ... - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - January 11 at 8:27 PM
News IconStock Reaching Most Volatile List Today: Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Wall Street Beacon (NASDAQ:ADAP)
wsbeacon.com - January 11 at 3:27 PM
News IconViolent muggers target elderly in Brooklyn (NASDAQ:ADAP)
www.newsoneplace.com - January 10 at 1:34 AM
us.rd.yahoo.com logoAdaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors (NASDAQ:ADAP)
us.rd.yahoo.com - January 10 at 1:34 AM
us.rd.yahoo.com logoAdaptimmune Announces New Senior Vice President of Global Bio-Process and Development (NASDAQ:ADAP)
us.rd.yahoo.com - January 10 at 1:34 AM
globenewswire.com logoAdaptimmune confirms GSK Nomination of Second Adaptimmune ... - GlobeNewswire (press release) (NASDAQ:ADAP)
globenewswire.com - January 9 at 3:32 PM
istreetwire.com logoInvestor’s Watch List: HP Inc. (HPQ), Groupon, Inc. (GRPN), Merck & Co., Inc. (MRK) (NASDAQ:ADAP)
istreetwire.com - January 4 at 3:24 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Prospect Journal (NASDAQ:ADAP)
prospectjournal.com - January 3 at 8:20 AM
News IconAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Under Analyst ... - UK Market News (NASDAQ:ADAP)
www.ukmarketnews.co.uk - December 30 at 3:19 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Prospect Journal (NASDAQ:ADAP)
prospectjournal.com - December 27 at 5:54 AM
seekingalpha.com logoDividend Growth Investors Want One Thing For Christmas And One Thing Only (NASDAQ:ADAP)
seekingalpha.com - December 23 at 3:23 PM
4-traders.com logoADAPTIMMUNE THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:ADAP)
www.4-traders.com - December 20 at 3:16 PM
4-traders.com logoAdaptimmune Therapeutics : and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies (NASDAQ:ADAP)
www.4-traders.com - December 20 at 9:21 AM
us.rd.yahoo.com logo7:30 am Adaptimmune Therapeutics and Bellicum Pharma (BLCM (NASDAQ:ADAP)
us.rd.yahoo.com - December 20 at 9:21 AM
biz.yahoo.com logoADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial (NASDAQ:ADAP)
biz.yahoo.com - December 20 at 9:21 AM
streetinsider.com logoAdaptimmune (ADAP) and Bellicum (BLCM) Enter Agreement to ... - StreetInsider.com (NASDAQ:ADAP)
www.streetinsider.com - December 19 at 3:25 PM
publicnow.com logoAdaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies (NASDAQ:ADAP)
www.publicnow.com - December 19 at 3:25 PM
insidermonkey.com logoIs Adaptimmune Therapeutics PLC (ADAP) A Good Stock To Buy? (NASDAQ:ADAP)
www.insidermonkey.com - December 17 at 8:19 PM
News IconAdaptimmune Therapeutics Plc (NASDAQ:ADAP) Analyst Coverage (NASDAQ:ADAP)
myhealthbowl.com - December 15 at 3:24 PM
investornewswire.com logoStrong Sell Recommendations Of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) At 0 - Investor Newswire (NASDAQ:ADAP)
www.investornewswire.com - December 14 at 8:30 PM

Social

What is Adaptimmune Therapeutics PLC -'s stock symbol?

Adaptimmune Therapeutics PLC - trades on the NASDAQ under the ticker symbol "ADAP."

Where is Adaptimmune Therapeutics PLC -'s stock going? Where will Adaptimmune Therapeutics PLC -'s stock price be in 2017?

5 equities research analysts have issued 1-year price targets for Adaptimmune Therapeutics PLC -'s stock. Their forecasts range from $15.00 to $16.00. On average, they expect Adaptimmune Therapeutics PLC -'s stock price to reach $15.50 in the next twelve months.

When will Adaptimmune Therapeutics PLC - announce their earnings?

Adaptimmune Therapeutics PLC - is scheduled to release their next quarterly earnings announcement on Thursday, November, 10th 2016.

Who owns Adaptimmune Therapeutics PLC - stock?

Adaptimmune Therapeutics PLC -'s stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (9.98%), Baillie Gifford & Co. (1.30%), FIL Ltd (1.06%), Orbimed Advisors LLC (1.02%), Renaissance Technologies LLC (0.63%) and Artal Group S.A. (0.00%). Company insiders that own Adaptimmune Therapeutics PLC - stock include Charles Elliott Sigal and Orbimed Advisors Llc.

Who bought Adaptimmune Therapeutics PLC - stock? Who is buying Adaptimmune Therapeutics PLC - stock?

Adaptimmune Therapeutics PLC -'s stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Artal Group S.A. and FIL Ltd. Company insiders that have bought Adaptimmune Therapeutics PLC - stock in the last two years include Charles Elliott Sigal and Orbimed Advisors Llc.

How do I buy Adaptimmune Therapeutics PLC - stock?

Shares of Adaptimmune Therapeutics PLC - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Adaptimmune Therapeutics PLC - stock cost?

One share of Adaptimmune Therapeutics PLC - stock can currently be purchased for approximately $3.95.

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)

Earnings History Chart

Earnings by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)

Dividend History Chart

Dividend Payments by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)

Last Updated on 2/27/2017 by MarketBeat.com Staff